These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12628833)

  • 1. Dose-adjusting epirubicin in patients with altered liver function: when classical pharmacology makes good practical sense.
    Gianni L
    Eur J Cancer; 2003 Mar; 39(5):557-9. PubMed ID: 12628833
    [No Abstract]   [Full Text] [Related]  

  • 2. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
    Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
    Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification.
    Twelves CJ; Richards MA; Smith P; Rubens RD
    Ann Oncol; 1991 Oct; 2(9):663-6. PubMed ID: 1742222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
    Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
    Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
    Twelves CJ; O'Reilly SM; Coleman RE; Richards MA; Rubens RD
    Br J Cancer; 1989 Dec; 60(6):938-41. PubMed ID: 2605102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transhepatic arterial chemoembolization by epirubicin mixed with microspheres for hepatocellular carcinoma].
    Luo JJ; Yan ZP; Wang JH; Liu QX; Chen Y
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):619-22. PubMed ID: 18210885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of 5'-nucleotidase, bilirubin, alkaline phosphatase and transaminase in liver diseases--a comparative study.
    Singh YN; Hameed F; Khan R; Husain Z
    Indian J Pathol Microbiol; 1987 Jan; 30(1):55-67. PubMed ID: 2824355
    [No Abstract]   [Full Text] [Related]  

  • 8. Liver injury and ascites in dengue.
    Bamanikar AA
    J Assoc Physicians India; 2014 Mar; 62(3):290-1. PubMed ID: 25327083
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
    Gurney HP; Ackland S; Gebski V; Farrell G
    J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of bilirubin in a liver screening panel.
    Brown AN; Sheiner LB; Cohen SN
    JAMA; 1992 Sep 23-30; 268(12):1542. PubMed ID: 1518108
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply from author.
    Shukla V
    J Assoc Physicians India; 2014 Mar; 62(3):291. PubMed ID: 25327084
    [No Abstract]   [Full Text] [Related]  

  • 12. Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
    Dobbs NA; Twelves CJ
    Br J Cancer; 1998 Apr; 77(7):1145-8. PubMed ID: 9569053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epirubicin in the treatment of malignant obstructive jaundice].
    Chen Y; Yan ZP; Wang JH; Wang XL; Cheng JM; Gong GQ; Liu QX; Qian S; Liu R; Luo JJ
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):397-9. PubMed ID: 17045011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
    Müller HJ; Grubert M; Hilger R; Richly H; Port R; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):575-7. PubMed ID: 12503820
    [No Abstract]   [Full Text] [Related]  

  • 15. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats.
    Shin DH; Park SH; Jeong SW; Park CW; Han K; Chung YB
    Arch Pharm Res; 2014 Dec; 37(12):1599-606. PubMed ID: 25373308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma.
    Higashi S; Tabata N; Kondo KH; Maeda Y; Shimizu M; Nakashima T; Setoguchi T
    J Pharmacol Exp Ther; 1999 May; 289(2):816-9. PubMed ID: 10215657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model.
    Okada M; Kudo S; Miyazaki O; Saino T; Ekimoto H; Iguchi H; Hirano S; Kuboki H; Kadosawa H; Takeuchi T
    Br J Cancer; 1995 Mar; 71(3):518-24. PubMed ID: 7880733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acetphenolisatin and liver damage].
    Fabricius-Bjerre N; Hertel K
    Ugeskr Laeger; 1973 Dec; 135(50):2745-6. PubMed ID: 4780574
    [No Abstract]   [Full Text] [Related]  

  • 20. [Biochemical indices of the blood serum in various liver diseases].
    Tokarskaia ZB; Chernova GV; Dorozhko VA
    Ter Arkh; 1974; 46(4):53-8. PubMed ID: 4139774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.